Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$252.16 +0.1%	$215.95	$96.09 ▼ $257.92	$12.96B	0.61	648,364 shs	519,440 shs
JAZZ Jazz Pharmaceuticals	$226.93 +0.0%	$220.08	$105.00 ▼ $243.32	$14.25B	0.32	841,481 shs	679,969 shs
TAK Takeda Pharmaceutical	$15.41 -1.6%	$16.54	$12.99 ▼ $18.90	$49.84B	-0.07	2.92 million shs	2.50 million shs
TEVA Teva Pharmaceutical Industries	$32.59 -1.0%	$33.46	$14.99 ▼ $37.35	$37.84B	0.84	5.79 million shs	5.54 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-0.59%	+2.55%	+10.62%	+59.57%	+147.72%
JAZZ Jazz Pharmaceuticals	-1.61%	-1.01%	-0.83%	+25.73%	+106.93%
TAK Takeda Pharmaceutical	-0.70%	-0.32%	-5.82%	-13.25%	+3.85%
TEVA Teva Pharmaceutical Industries	-2.31%	-4.29%	-4.11%	+11.07%	+87.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$252.16 +0.1%	$215.95	$96.09 ▼ $257.92	$12.96B	0.61	648,364 shs	519,440 shs
JAZZ Jazz Pharmaceuticals	$226.93 +0.0%	$220.08	$105.00 ▼ $243.32	$14.25B	0.32	841,481 shs	679,969 shs
TAK Takeda Pharmaceutical	$15.41 -1.6%	$16.54	$12.99 ▼ $18.90	$49.84B	-0.07	2.92 million shs	2.50 million shs
TEVA Teva Pharmaceutical Industries	$32.59 -1.0%	$33.46	$14.99 ▼ $37.35	$37.84B	0.84	5.79 million shs	5.54 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-0.59%	+2.55%	+10.62%	+59.57%	+147.72%
JAZZ Jazz Pharmaceuticals	-1.61%	-1.01%	-0.83%	+25.73%	+106.93%
TAK Takeda Pharmaceutical	-0.70%	-0.32%	-5.82%	-13.25%	+3.85%
TEVA Teva Pharmaceutical Industries	-2.31%	-4.29%	-4.11%	+11.07%	+87.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.95	Moderate Buy	$258.95	2.69% Upside
JAZZ Jazz Pharmaceuticals	2.79	Moderate Buy	$246.06	8.43% Upside
TAK Takeda Pharmaceutical	2.50	Moderate Buy	N/A	N/A
TEVA Teva Pharmaceutical Industries	2.80	Moderate Buy	$41.78	28.21% Upside

Current Analyst Ratings Breakdown

Latest AXSM, JAZZ, TAK, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2026	AXSM Axsome Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$275.00 ➝ $300.00
6/15/2026	AXSM Axsome Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/12/2026	JAZZ Jazz Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
6/11/2026	AXSM Axsome Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$380.00
6/11/2026	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Overweight
6/10/2026	JAZZ Jazz Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$281.00 ➝ $307.00
6/9/2026	JAZZ Jazz Pharmaceuticals	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
6/9/2026	JAZZ Jazz Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$256.00
6/4/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/27/2026	JAZZ Jazz Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$234.00 ➝ $253.00
5/26/2026	JAZZ Jazz Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)

(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$638.50M	20.32	N/A	N/A	$1.75 per share	144.09
JAZZ Jazz Pharmaceuticals	$4.27B	3.34	$16.27 per share	13.95	$71.07 per share	3.19
TAK Takeda Pharmaceutical	$28.32B	1.73	$3.05 per share	5.05	$16.12 per share	0.96
TEVA Teva Pharmaceutical Industries	$17.26B	2.17	$3.69 per share	8.82	$6.88 per share	4.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.73	N/A	51.99	N/A	-26.59%	-267.16%	-28.53%	8/3/2026 (Estimated)
JAZZ Jazz Pharmaceuticals	-$356.15M	-$0.02	N/A	10.15	0.20	0.66%	14.56%	5.25%	8/4/2026 (Estimated)
TAK Takeda Pharmaceutical	$1.27B	$0.39	39.50	12.63	N/A	4.31%	11.07%	5.49%	7/30/2026 (Estimated)
TEVA Teva Pharmaceutical Industries	$1.41B	$1.33	24.50	10.72	3.36	9.01%	43.53%	8.19%	7/29/2026 (Estimated)

Latest AXSM, JAZZ, TAK, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2026	Q1 2026	JAZZ Jazz Pharmaceuticals	$4.67	$6.34	+$1.67	$4.43	$978.66 million	$974.98 million
5/4/2026	Q1 2026	AXSM Axsome Therapeutics	-$0.85	-$1.26	-$0.41	-$1.26	$191.10 million	$191.20 million
4/29/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	$0.50	$0.53	+$0.03	$0.31	$3.79 billion	$3.98 billion
3/31/2026	Q1 2026	JAZZ Jazz Pharmaceuticals	N/A	$6.34	N/A	$4.43	N/A	$1.07 billion
3/31/2026	Q4 2025	TAK Takeda Pharmaceutical	N/A	$0.5610	N/A	-$0.0483	N/A	$6.90 billion
3/31/2026	Q1 2026	TEVA Teva Pharmaceutical Industries	N/A	$0.53	N/A	$0.31	N/A	$3.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.25	1.62%	-18.61%	64.10%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	2.27	1.39	1.32
JAZZ Jazz Pharmaceuticals	0.95	2.04	1.85
TAK Takeda Pharmaceutical	0.56	1.27	0.70
TEVA Teva Pharmaceutical Industries	1.70	1.01	0.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
JAZZ Jazz Pharmaceuticals	89.14%
TAK Takeda Pharmaceutical	9.17%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
JAZZ Jazz Pharmaceuticals	4.10%
TAK Takeda Pharmaceutical	0.04%
TEVA Teva Pharmaceutical Industries	0.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	51.46 million	40.86 million	Optionable
JAZZ Jazz Pharmaceuticals	2,890	62.82 million	60.24 million	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
TEVA Teva Pharmaceutical Industries	33,950	1.15 billion	1.14 billion	Optionable

AXSM, JAZZ, TAK, and TEVA Headlines

Recent News About These Companies

Mangrove Partners IM LLC Has $67.38 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

June 17 at 5:48 AM | marketbeat.com

Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells 106,563 Shares of Stock

June 17 at 5:45 AM | insidertrades.com

Polar Capital Holdings Plc Purchases 978,608 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

June 17 at 5:13 AM | marketbeat.com

Medincell SA (STU:MEB) Full Year 2026 Earnings Call Highlights: Strategic Growth and Challenges

June 16 at 12:34 AM | finance.yahoo.com

Atlas Capital Advisors Inc. Buys Shares of 31,944 Teva Pharmaceutical Industries Ltd. $TEVA

June 15 at 3:09 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Stock Holdings Decreased by Avidity Partners Management LP

June 14 at 4:22 AM | marketbeat.com

Teva Refocuses On Higher‑Margin Drugs With Emalex Deal And API Cuts

June 13, 2026 | finance.yahoo.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by Clal Insurance Enterprises Holdings Ltd

June 13, 2026 | marketbeat.com

June 12, 2026 | fool.com

Teva Pharmaceutical closes acquisition of Emalex Biosciences

June 12, 2026 | pharmabiz.comP

173,075 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Marsico Capital Management LLC

June 12, 2026 | marketbeat.com

Private Management Group Inc. Reduces Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

June 12, 2026 | marketbeat.com

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

June 11, 2026 | finance.yahoo.com

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

June 11, 2026 | businesswire.com

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

June 10, 2026 | finance.yahoo.com

Teva Pharmaceutical Industries Ltd. Completes Acquisition of Emalex Biosciences to Enhance Tourette Syndrome Treatment Pipeline with Ecopipam

June 10, 2026 | quiverquant.comQ

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

June 10, 2026 | globenewswire.com

Teva’s data on Austedo highlight long-term advances in treatment of tardive dyskinesia

June 10, 2026 | pharmabiz.comP

TIAA Trust National Association Sells 237,843 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

June 10, 2026 | marketbeat.com

2,361,012 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Bought by Capital World Investors

June 10, 2026 | marketbeat.com

Is Amneal a Buy Before Rytary Generic Erosion?

June 9, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AXSM, JAZZ, TAK, and TEVA Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$252.16 +0.25 (+0.10%)

Closing price 04:00 PM Eastern

Extended Trading

$254.55 +2.39 (+0.95%)

As of 07:37 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Jazz Pharmaceuticals NASDAQ:JAZZ

$226.93 +0.05 (+0.02%)

Closing price 04:00 PM Eastern

Extended Trading

$226.96 +0.03 (+0.01%)

As of 07:53 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Takeda Pharmaceutical NYSE:TAK

$15.40 -0.26 (-1.63%)

Closing price 03:59 PM Eastern

Extended Trading

$15.40 0.00 (0.00%)

As of 07:08 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries NYSE:TEVA

$32.58 -0.33 (-0.99%)

Closing price 03:59 PM Eastern

Extended Trading

$32.54 -0.04 (-0.14%)

As of 07:48 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AXSM, JAZZ, TAK, and TEVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AXSM, JAZZ, TAK, and TEVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AXSM, JAZZ, TAK, and TEVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AXSM, JAZZ, TAK, and TEVA Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Jazz Pharmaceuticals NASDAQ:JAZZ

Takeda Pharmaceutical NYSE:TAK

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AXSM, JAZZ, TAK, and TEVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AXSM, JAZZ, TAK, and TEVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AXSM, JAZZ, TAK, and TEVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AXSM, JAZZ, TAK, and TEVA Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Jazz Pharmaceuticals NASDAQ:JAZZ

Takeda Pharmaceutical NYSE:TAK

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools